RespireRx Pharmaceuticals Inc
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the CB1 and CB2 endocannabinoid receptors for use in chemotherapy-induced nausea and vomiting, … Read more
Market Cap & Net Worth: RespireRx Pharmaceuticals Inc (RSPI)
RespireRx Pharmaceuticals Inc (PINK:RSPI) has a market capitalization of $21.98 ($21.98) as of March 19, 2026. Listed on the PINK stock exchange, this USA-based company holds position #36479 globally and #11869 in its home market, demonstrating a 27.78% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying RespireRx Pharmaceuticals Inc's stock price $0.00 by its total outstanding shares 9555 (9.55K).
RespireRx Pharmaceuticals Inc Market Cap History: 2015 to 2025
RespireRx Pharmaceuticals Inc's market capitalization history from 2015 to 2025. Data shows change from $577.60K to $21.98 (-66.91% CAGR).
RespireRx Pharmaceuticals Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how RespireRx Pharmaceuticals Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.65x
RespireRx Pharmaceuticals Inc's market cap is 6.65 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $577.60K | $86.92K | -$5.96 Million | 6.65x | N/A |
Competitor Companies of RSPI by Market Capitalization
Companies near RespireRx Pharmaceuticals Inc in the global market cap rankings as of March 19, 2026.
Key companies related to RespireRx Pharmaceuticals Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
RespireRx Pharmaceuticals Inc Historical Marketcap From 2015 to 2025
Between 2015 and today, RespireRx Pharmaceuticals Inc's market cap moved from $577.60K to $ 21.98, with a yearly change of -66.91%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $21.98 | +228.57% |
| 2024 | $6.69 | -22.22% |
| 2023 | $8.60 | -60.87% |
| 2022 | $21.98 | -80.34% |
| 2021 | $111.79 | -59.66% |
| 2020 | $277.10 | -97.10% |
| 2019 | $9.55K | -84.62% |
| 2018 | $62.11K | -42.98% |
| 2017 | $108.93K | -59.29% |
| 2016 | $267.54K | -53.68% |
| 2015 | $577.60K | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of RespireRx Pharmaceuticals Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $21.98 USD |
| MoneyControl | $21.98 USD |
| MarketWatch | $21.98 USD |
| marketcap.company | $21.98 USD |
| Reuters | $21.98 USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.